UBS AG set a GBX 4,550 ($59.84) price target on AstraZeneca plc (LON:AZN) in a report issued on Thursday. The firm currently has a neutral rating on the biopharmaceutical company’s stock.
A number of other equities analysts have also issued reports on AZN. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a research report on Thursday. Citigroup Inc. restated a buy rating on shares of AstraZeneca plc in a research note on Wednesday. Investec reissued a buy rating and issued a GBX 5,500 ($72.34) price target (up previously from GBX 4,900 ($64.45)) on shares of AstraZeneca plc in a research note on Monday, November 6th. Jefferies Group LLC restated a hold rating and issued a GBX 5,100 ($67.08) price objective on shares of AstraZeneca plc in a report on Monday, November 6th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 3,800 ($49.98) target price on AstraZeneca plc and gave the company a sell rating in a report on Thursday, November 2nd. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of Hold and an average target price of GBX 5,247.18 ($69.01).
Shares of AstraZeneca plc (AZN) traded down GBX 92 ($1.21) during trading hours on Thursday, hitting GBX 4,870 ($64.05). The stock had a trading volume of 3,189,397 shares, compared to its average volume of 1,940,000. AstraZeneca plc has a 1-year low of GBX 3,996 ($52.56) and a 1-year high of GBX 5,520 ($72.60).
COPYRIGHT VIOLATION WARNING: “AstraZeneca plc (AZN) Given a GBX 4,550 Price Target at UBS AG” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/11/astrazeneca-plc-azn-given-a-gbx-4550-price-target-at-ubs-ag-2.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.